prikaz prve stranice dokumenta Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
  Preuzmi
PDF 2.44 MB
Znanstveni rad - Izvorni znanstveni rad
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
Bone Marrow Transplantation, 58 (2023), 6; 647-658. https://doi.org/10.1038/s41409-023-01943-3
Passweg, Jakob R.; Baldomero, Helen; Ciceri, Fabio; Corbacioglu, Selim; de la Cámara, Rafael; Dolstra, Harry; Glass, Bertram; Greco, Raffaella; McLornan, Donal P.; Neven, Bénédicte; de Latour, Régis Peffault; Perić, Zinaida; Ruggeri, Annalisa; Snowden, John A.; Sureda, Anna Više autora...

Citirajte ovaj rad

Passweg, J. R., Baldomero, H., Ciceri, F., Corbacioglu, S., de la Cámara, R., Dolstra, H. ... Sureda, A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58. (6), 647-658. doi: 10.1038/s41409-023-01943-3

Passweg, Jakob R., et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey." Bone Marrow Transplantation, vol. 58, br. 6, 2023, str. 647-658. https://doi.org/10.1038/s41409-023-01943-3

Passweg, Jakob R., Helen Baldomero, Fabio Ciceri, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glass, et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey." Bone Marrow Transplantation 58, br. 6 (2023): 647-658. https://doi.org/10.1038/s41409-023-01943-3

Passweg, J. R., et al. (2023) 'Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey', Bone Marrow Transplantation, 58(6), str. 647-658. doi: 10.1038/s41409-023-01943-3

Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, i sur.. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation [Internet]. 06.2023. [pristupljeno 07.05.2024.];58(6):647-658. doi: 10.1038/s41409-023-01943-3

J. R. Passweg, et al., "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey", Bone Marrow Transplantation, vol. 58, br. 6, str. 647-658, Lipanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:854441. [Citirano: 07.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:854441
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
AutorJakob R. Passweg
AutorHelen Baldomero
AutorFabio Ciceri
AutorSelim Corbacioglu
AutorRafael de la Cámara
AutorHarry Dolstra
AutorBertram Glass
AutorRaffaella Greco
AutorDonal P. McLornan
AutorBénédicte Neven
AutorRégis Peffault de Latour
AutorZinaida Perić
AutorAnnalisa Ruggeri
AutorJohn A. Snowden
AutorAnna Sureda
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5.4%, autologous HCT +3.9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%). Main indications for autologous HCT were lymphoid malignancies 22,129 (90%) and solid tumors 1635 (7%). In allogeneic HCT, use of haploidentical donors decreased by −0.9% while use of unrelated and sibling donors increased by +4.3% and +9%. Cord blood HCT decreased by −5.8%. Pediatric HCT increased overall by +5.6% (+6.9% allogeneic and +1.6% autologous). Increase in the use of CAR-T was mainly restricted to high-income countries. The drop in HCT activity reported in 2020 partially recovered in 2021, the second year of the SARS-CoV-2 pandemic. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual EBMT report reflects current activities useful for health care resource planning.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBone Marrow Transplantation
Brojčani podacivol. 58, br. 6, str. 647-658
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-023-01943-3
URN:NBNurn:nbn:hr:105:854441
Datum objave publikacije2023-06
URL dokumentahttps://www.nature.com/articles/s41409-023-01943-3
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-12 09:05:26